Tuberculosis: Extracting Value From a Stagnant Market
| Brief No. | | Published |
|
| | |
| |
The TB treatment and prophylaxis market has experienced limited growth and activity over the last 40 years, as companies have perceived TB as primarily a "poor disease". However, the market now looks to hold greater potential, with rising incidence in the US, and improved diagnostics creating a renewed demand for both vaccination and therapeutics.
Overview of TB pathology and epidemiology Review of current TB diagnostic technologies and areas of unmet need in the diagnostics market Assessment of current TB treatment, highlighting areas of unmet need and potential market opportunity Analysis of the prophylaxis market providing strategic insight into clinical trial design and strategies for market penetration
There are three key areas within the TB market with high levels of unmet need, namely diagnostics, therapeutics, and prophylaxis. TB vaccines with higher efficacy and longevity will help to persuade governments in the developed world to reconsider including TB prophylaxis in immunization schedules. Improvements in the rapidity and accuracy of diagnostic technologies will drive patient potential and market growth. The development of second line treatment options for resistant infection will increase the value of the TB treatment market.
Identify the areas of the TB market which offer the highest potential for new market entrants Understand the changing competitive dynamics in the TB market Identify the key epidemiological trends for TB in the major markets |
